PIK3CA-mutations in breast cancer

• DOI: 10.1007/s10549-022-06637-w
• Publication Date: 2022-10-24T13:03:12Z
• Authors: Kristin Reinhardt; Kathrin Stückrath; Carolin Hartung; Sandy Kaufhold; Christoph Uleer; Volker Hanf; Tillmann Lantzsch; Susanne Peschel; Jutta John; Marleen Pöhler; Marcus Bauer; Friedrich Karl Bü...; Edith Weigert; Jörg Buchmann; Eva Johanna Kante...; Christoph Thomssen; Martina Vetter
• Keywords: ddc:610; 0303 health sciences; Receptor, ErbB-2; Class I Phosphatidylinositol 3-Kinases; 610; Breast Neoplasms; 3. Good health; Cohort Studies; 03 medical and health sciences; Preclinical Study; Mutation; Humans; Female

Abstract Purpose Phosphatidylinositide-3-kinase (PI3K) regulates proliferation and apoptosis; somatic PIK3CA-mutations may activate these processes. Aim of this study was to determine the prevalence of PIK3CA-mutations in a cohort of early stage breast cancer patients and the association to the course of disease.

Patients and methods From an unselected cohort of 1270 breast cancer patients (PiA, Prognostic Assessment in routine application, NCT 01592825) 1123 tumours were tested for the three PIK3CA hotspot-mutations H1047R, E545K, and E542K by qPCR. Primary objectives were the prevalence of somatic PIK3CA-mutations and their association to tumour characteristics. Secondary objective was the association of PIK3CA-mutations to recurrence-free interval (RFI) and overall survival.

Results PIK3CA-mutation rate was 26.7% (300 of 1123). PIK3CA-mutations were significantly more frequent in steroid hormone-receptor (SHR)-positive HER2-negative (31.4%), and G1 and G2 tumours (32.8%). Overall, we did not observe a significant association of PIK3CA-mutations to RFI. In SHR-positive BCs with PIK3CA-mutations, a strong trend for impaired RFI was observed (adjusted HR 1.64, 95% CI 0.958–2.807), whilst in SHR-negative BCs PIK3CA-mutations were insignificantly associated with improved RFI (adjusted HR 0.49; 95% CI 0.152–1.597). Of note, we observed a significantly detrimental prognostic impact of PIK3CA-mutations on RFI in SHR-positive, HER2-negative BCs if only aromatase inhibitors were administered as adjuvant therapy (adjusted HR 4.44, 95% CI 1.385–13.920), whilst no impact was observed in tamoxifen treated patients.

Conclusion This cohort study speficies the overall mutation rate of PIK3CA in early breast cancer. The impact of PIK3CA-mutations on RFI and OS was heterogeneous. Our results suggest that estrogen deprivation failes to be active in case of PIK3CA-mutation.